Dr. Mailankody is a medical oncologist with the Myeloma Service and a member of the Cellular Therapeutics Center and the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center. His research focuses on the clinical development of novel immune and cellular therapies for patients with multiple myeloma and translational research focused on better understanding responses to cellular therapies and possible mechanisms of relapse. Dr. Mailankody is the principal investigator for multiple chimeric antigen receptor (CAR) T-cell trials for multiple myeloma, including the first trials of an allogeneic CAR T-cell therapy and autologous GPRC5D CAR T cells for myeloma.